Affordable Access

Zidovudine plus lamivudine in Human T-Lymphotropic Virus type-I-associated myelopathy: a randomised trial.

Authors
  • Taylor, Graham P
  • Goon, Peter
  • Furukawa, Yoshitaka
  • Green, Hannah
  • Barfield, Anna
  • Mosley, Angelina
  • Nose, Hirohisa
  • Babiker, Abdel
  • Rudge, Peter
  • Usuku, Koichiro
  • Osame, Mitsuhiro
  • Bangham, Charles R M
  • Weber, Jonathan N
Type
Published Article
Journal
Retrovirology
Publisher
Springer (Biomed Central Ltd.)
Publication Date
Jan 01, 2006
Volume
3
Pages
63–63
Identifiers
PMID: 16984654
Source
Medline
License
Unknown

Abstract

Failure to detect clinical improvement may have been due irreversible nerve damage in these patients with a long clinical history and future studies should target patients presenting earlier. The lack of virological effect but may reflect a lack of activity of these nucleoside analogues against HTLV-I RT in vivo, inadequate intracellular concentrations of the active moiety or the contribution of new cell infection to maintaining proviral load at this stage of infection may be relatively small masking the effects of RT inhibition.

Report this publication

Statistics

Seen <100 times